Foshan First People's Hospital Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4

Organization Overview

First Clinical Trial
2017
NCT03123406
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Foshan First People 's Hospital | Foshan First People's Hospital

Active Ingredients

Drugs in Phase 4 Trials (1)

cinacalcet (sensipar) (1 trial)

Drugs in Phase 3 Trials (3)

Epimedium (2 trials)

huachansu pian (1 trial)

sorafenib (nexavar) (1 trial)

Drugs in Phase 2 Trials (2)

lenalidomide (revlimid) (1 trial)

rituximab (rituxan) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 3)

Carcinoma, Hepatocellular (Phase 3)

Hyperparathyroidism (Phase 4)

Hyperparathyroidism, Secondary (Phase 4)

Lymphoma (Phase 2)

Lymphoma, B-Cell (Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 2)

Neoplasm Metastasis (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 4
  • # of Trial APIs: 6